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Abstract 
N-methyl-D-aspartate receptor (NMDAR) mediated excitotoxicity is implicated as a 
proximate cause of neurodegeneration in Huntington Disease (HD).  However, this 
hypothesis has not been tested rigorously in vivo.  NMDAR NR2B-subunits are the 
predominant NR2 subunit expressed by the striatal medium spiny neurons that degenerate 
in HD.  To test this hypothesis, we crossed a well validated murine genetic model of HD 
(Hdh(CAG)150) with a transgenic line overexpressing NMDAR NR2B-subunits.  In the 
resulting double mutant line, we show exacerbation of selective striatal neuron 
degeneration.  These results provide the first direct in vivo evidence of NR2B-NMDAR 
mediated excitotoxicity in the context of HD.  Our results are consistent with prior 
suggestions that direct and/or indirect interactions of mutant huntingtin with NMDARs 
are a proximate cause of neurodegeneration in HD.  
 INTRODUCTION 
Huntington disease (HD) is a dominantly inherited neurodegenerative disorder caused by 
expanded CAG repeat/polyglutamine repeats within the huntingtin locus resulting in a 
pathogenic huntingtin protein (htt).  Early and prominent neurodegeneration of striatal 
GABAergic medium spiny neurons (MSNs) is a pathologic hallmark of HD.  Clinical 
manifestations include progressive cognitive decline, psychiatric disturbances, and 
involuntary movements.  HD is incurable and death follows inexorably approximately 15 
– 20 years after diagnosis.  The striatum is the primary afferent structure of the basal 
ganglia, is composed predominantly of MSNs, and is involved in numerous important 
functions including habit formation and evaluation of rewarded behaviors1, 2.  Although 
the molecular and cellular mechanisms underlying the selective degeneration of MSNs in 
HD are not yet understood, convergent evidence from a variety of sources supports a role 
for N-methyl-D-aspartate receptor (NMDAR) mediated excitotoxicity3-7.  
The striatum receives an abundance of glutamatergic corticostriatal and 
thalamostriatal inputs, and MSNs are endowed heavily with NMDARs and other 
glutamate receptors2.  Coyle and Schwarcz and the McGeers developed the first chemical 
model of HD with demonstrations that acute intrastriatal administration of the glutamate 
agonist kainic acid in rodents produced neurodegeneration with features similar to HD4, 5.  
Considerable later work indicated that acute striatal lesions with NMDAR selective 
agonists reproduced more features of striatal pathology in HD3, 8-11.  This is true for both 
NMDAR agonists and metabolic inhibitors whose indirect effects facilitate NMDAR 
activation12, 13.  While the correlation between the effects of acutely administered 
NMDAR agonists and HD striatal pathology is impressive, the NMDAR excitotoxicity 
hypothesis of striatal degeneration in HD has not been previously tested rigorously in 
vivo.  
NMDARs are hetero-multimeric ionotropic receptors that mediate extracellular 
calcium entry and consist of NR1 subunits and NR2 (A-D) subunits14, 15.  Comparative 
studies confirm that the pharmacological and functional properties of the NMDA receptor 
depend heavily on NR2 subunit composition16-18.  In some model systems, NR2B-
containing NMDARs promote pro-death signaling opposed to the pro-survival promoting 
pathways of NR2A-containing NMDARs19-22. NR2B subunit containing NMDARs are 
highly expressed by MSNs and predominate over other subunit compositions, such as the 
NR1/NR2A, in the striatum23.  Previous in vitro studies suggest sensitization of NR2B 
function by mutant htt7, 24. 
To determine whether striatal pathology and behavioral deficits of HD are caused 
by NMDAR-mediated excitotoxic injury in vivo, we created a modified murine model of 
excitotoxic injury by crossing a well validated murine genetic model of HD to a 
transgenic mouse overexpressing the NMDAR NR2B-subunits25, 26.  In this double 
mutant mouse line, we demonstrate exacerbation of striatal pathology characteristic of 
HD.   
RESULTS 
Hdh150/+; NR2BTg/WT Double Mutant Mice Exhibit Striatal Neuron Loss and 
Decreased Striatal Dopamine Receptors  
At 100 weeks of age, Hdh150/+; NR2BTg/WT double mutant mice displayed atrophic and 
irregularly shaped striatal neurons compared to controls (Hdh+/+; NR2BWT/WT, Hdh+/+; 
NR2BTg/WT and Hdh150/+; NR2BWT/WT; Fig. 1a-d).  The Hdh150/+; NR2BTg/WT double 
mutants exhibited marked decreases in striatal volume and neuron number with a mean 
36% decrease in striatal volume, and a 51% mean decrease in striatal neuron number 
compared to all three control groups (Hdh+/+; NR2BWT/WT, Hdh+/+; NR2BTg/WT and 
Hdh150/+; NR2BWT/WT; Fig. 1e and f).  At 70 weeks, there was no decrease in striatal 
neuron number or volume.   
 Striatal pathology observed in the double mutant mice was confirmed by loss of 
striatal dopamine D1 and D2 receptors (Fig. 2 and supplemental Table 1).  The 
Hdh150/+; NR2BTg/WT double mutant mice exhibited an average 37% reduction of D1 
receptor binding in the substantia nigra (SN) compared to both the Hdh+/+; NR2BWT/WT 
and Hdh+/+; NR2BTg/WT wild type mice at 100 weeks.  The Hdh150/+; NR2BTg/WT 
double mutant mice showed a 48% decrease in the ventral striatum and a 43% reduction 
in the dorsal striatum compared to both Hdh+/+; NR2BWT/WT and Hdh+/+; NR2BTg/WT 
wild type mice at 100 weeks (Fig. 2a).  Although not significantly different, Hdh150/+; 
NR2BWT/WT mice exhibit a decrease of D1 receptor binding intermediate between the 
Hdh+/+; NR2BWT/WT, Hdh+/+; NR2BTg/WT wild type controls and Hdh150/+; NR2BTg/WT 
double mutant mice.  Hdh150/+; NR2BTg/WT double mutants exhibited a 44% reduction in 
the ventral striatum and a 53% reduction in the dorsal striatum of D2 receptor binding at 
100 weeks compared to Hdh+/+; NR2BWT/WT wild type controls, and Hdh150/+; 
NR2BWT/WT again displayed an intermediate effect.  GABAA/benzodiazepine receptor 
binding was used to survey multiple extrastriatal brain regions and revealed no 
differences between groups at 100 weeks, indicating little or no neuronal loss in these 
brain regions (Fig. 2a).  Decreased D1 and D2 receptor binding was observed in double 
mutants at 70 weeks (Fig. 2b).  The Hdh150/+; NR2BTg/WT double mutant mice and 
Hdh150/+; NR2BWT/WT mice displayed similar average reductions in D1 and D2 receptor 
binding sites in both the dorsal and ventral striatum.  Both D1 and D2 receptor binding 
decreases approximated 30% (Fig. 2c).  Striatal dopamine transporters were additionally 
measured and were normal in all groups (data not shown).  
Hdh150/+; NR2BTg/WT Double Mutant Mice Exhibit No Change in Distribution of 
NIIs 
We determined the distribution of huntingtin aggregates in brain.  Neuronal 
intranuclear inclusions (NIIs) saturated striatal neurons in double mutant and Hdh150/+; 
NR2BWT/WT mice at 100 weeks (Fig. 3).  There were only sparse NIIs in other brain 
regions.  This result is consistent with selective striatal pathology in both double mutant 
and Hdh150/+; NR2BWT/WT mice and is consistent with our prior observations in the 
Hdh(CAG)150 line27.  With QRT-PCR, we determined that the presence of the NR2B 
transgene did not affect huntingtin mRNA expression (data not shown).   
Hdh150/+; NR2BTg/WT Double Mutant Mice Exhibit Weight Loss and Motor Deficits 
 Hdh150/+; NR2BTg/WT double mutant mice exhibited an 18.4% decrease in body 
weight compared to other groups [Fig. 4; Hdh150/+; NR2BTg/WT, 29.4 ± 3.1 g (mean ± 
SEM); Hdh+/+; NR2BWT/WT, 35.7 ± 1.4 g; Hdh+/+; NR2BTg/WT, 36.7 ± 4.5 g; Hdh150/+; 
NR2BWT/WT, 35.6 ± 3.9 g; p < 0.05].  No gross motor abnormalities were detected by the 
accelerated rotarod with all groups exhibiting similar latencies to fall.  The double mutant 
mice exhibited significantly reduced general locomotion and exploratory behavior at 100 
weeks [Fig. 5a; Hdh150/+; NR2BTg/WT, 76.8 ± 17.7 g (mean ± SEM) crossovers/ 2 hr; 
Hdh+/+; NR2BWT/WT, 251.7 ± 30.7; Hdh+/+; NR2BTg/WT, 199.1 ± 43.7 g; Hdh150/+; 
NR2BWT/WT, 102.8 ± 5.1 g; p < 0.01].  All groups displayed similar latencies to fall on the 
hanging wire test, indicating that muscle strength was not compromised by the presence 
of the mutant htt allele or the NR2B transgene (data not shown).  Double mutant mice 
had more difficulty traversing an 11mm round beam at 100 weeks (Fig. 5b).  Both 
Hdh150/+; NR2BTg/WT and Hdh150/+; NR2BWT/WT require three times as long to traverse 
the balance beam compared to wild type littermate controls [Hdh150/+; NR2BTg/WT, 5.8 ± 
0.4 s (mean ± SEM) seconds; Hdh150/+; NR2BWT/WT, 6.5 ± 0.6 s; Hdh+/+; NR2BWT/WT, 
2.0 ± 0.2; p < 0.05].  Footprint analysis revealed that both Hdh150/+; NR2BTg/WT and 
Hdh150/+; NR2BWT/WT display a shortening of stride length and loss of normal gait 
pattern compared to controls (Supplementary Fig. 1 online).  
DISCUSSION 
We tested the hypothesis that the selective striatal degeneration observed in HD is 
mediated by the NR2B subunit of the NMDAR in vivo.  In support of this hypothesis, we 
found that double mutant mice exhibited a significant decrease in striatal neuron number 
and striatal volume.  The striatal degeneration observed in these mice was associated with 
decreases in dopamine D1 and D2 receptor binding, and with motor deficits.  These data 
demonstrate synergistic effects of mutant htt and overexpression of NR2B subunits with 
exacerbation of the HD-like phenotype characteristic of Hdh(CAG)150 mice.  The NR2B 
transgenic line has previously been shown to exhibit increased NMDAR activation 
resulting in longer excitatory postsynaptic potentials (EPSPs) and increased calcium 
flux25.  In situ hybridization reveals increased expression of the NR2B transgene in the 
cortex, striatum, hippocampus, and amygdala with little increase of expression in 
thalamus, brainstem, and cerebellum25.  Within areas of increased NR2B expression, the 
total number of NR2B-containing NMDAR is increased in individual synapses.  These 
mice display normal growth, body weight, and behavior, and no anatomical abnormalities 
are reported25.  Interestingly, while our double mutant mice exhibited exacerbation of 
striatal neuron degeneration, the time course of their disease was not altered by the 
addition of the NR2B transgene.  
 Our results are consistent with prior work in other HD murine models supporting 
a role for NMDAR mediated excitotoxicity in HD.  Studies in transgenic mouse models 
of HD reveal evidence of increased NMDAR activation.  Cultured striatal neurons from 
YAC transgenic mice expressing a full length human HD gene exhibit increased 
NMDAR activation followed by increased Ca2+ levels and mitochondrial membrane 
depolarization in MSNs compared to wild type controls28, 29.  Striatal neurons in these 
transgenic models appear more susceptible to NMDA agonist mediated toxicity 
compared to wild type mice, and NMDA induced cell death is abolished by a specific 
NR2B antagonist30, 31.  Consistent with these results, the R6/2 transgenic mouse model of 
HD expressing exon 1 of the human HD exhibits selective increased NMDA-evoked 
current and enhancement of intracellular calcium30.  Conversely, recent work shows 
amelioration of behavioral and neuropathological deficits, and increased survival of R6/2 
transgenic mice with decortication, an antiexcitotoxic intervention32.  These observations 
support an important role for NMDAR action, particularly the NR2B subunit, in striatal 
neuron degeneration in HD. 
Comparative studies confirm that the pharmacological and functional properties 
of NMDARs depend heavily on NR2 subunit composition16-18.  NR2B subunit presence 
influences Mg2+ sensitivity and confers high Ca+2 permeability33.  NMDAR activation 
may either promote neuronal survival or cause excitotoxic injury34.  NMDAR effects on 
survival or death in some CNS neurons heavily depends on NR2 subunit composition.  In 
some model systems, NR2B-containing NMDARs promote pro-death signaling opposed 
to the pro-survival promoting pathways of NR2A-containing NMDARs19-22. Although 
extrasynaptic versus synaptic compartmentalization of NR2A- and NR2B-containing 
NMDAR potentially plays a role in modulating the interplay of cell death and survival 
pathway, recent evidence suggests that subunit composition is more salient in 
determining the balance between cell death and survival pathways21, 35.  NR2B subunit 
containing NMDARs are highly expressed by MSNs and predominate over other subunit 
composition, such as the NR1/NR2A, in the striatum23.  Previous in vitro studies indicate 
sensitization of NR2B function by mutant htt7, 24.   
Recent in vitro work directly links sensitization of NMDAR-NR2B dysfunction 
mediated by mutant htt to deranged intracellular Ca2+ homeostasis and apoptosis in HD20, 
36-38.  In an experiment linking expanded polyQ and elevated cytosolic Ca2+ levels 
resulting to apoptosis of cultured striatal neurons from a transgenic mouse model of HD, 
Tang and colleagues propose sensitization of expanded polyQ on NR1/NR2B containing 
NMDARs39.  Coexpression of NMDARs with expanded polyglutamine htt in non-
neuronal cultured cells enhances excitotoxic cell death, an effect maximized by NR2B 
subunit expression7, 40.  Similarly, cultured MSNs from a mouse model of HD exhibit 
increased glutamate evoked peak currents and enhanced Ca2+ levels mediated by the 
NR2B subunit24.  These findings support the hypothesis that mutant htt enhances 
neuronal susceptibility to NMDAR mediated excitotoxic insult, particularly in neurons 
expressing NR2B containing NMDARs17, 31, 39, 41. 
 Other mechanistic hypotheses of HD pathogenesis have been suggested, such as 
transcriptional dysregulation, axonal transport defects, brain-derived neurotropic factor 
(BDNF) depletion, and proteosomal dysfunction.  All these hypotheses have some 
support42-44.  It is possible that expanded polyQ huntingtin is neurotoxic because it has 
multiple deleterious effects45.  While our work supports NMDAR excitotoxicity as a 
proximate cause of neurodegeneration in HD, it is important to consider whether there is 
one pathway leading to neurodegeneration in HD, a primary pathway resulting in 
multiple secondary pathways, or an overlapping network of expanded polyQ effects 
resulting in neurodegeneration.  Interestingly, while the double mutants exhibit 
exacerbation of the phenotype they do not show any apparent change in the time course 
of the severity of the phenotype and exhibit similar pathological and behavioral changes 
to the Hdh(CAG)150 mice up to 70 weeks, suggesting that NMDAR excitotoxicity is a 
relatively late event in the pathogenesis of neurodegeneration in HD.  This inference 
would be consistent with suggestions of a multiple step, complex pathway(s) of 
neurodegeneration in HD43.  Our in vivo findings are consistent with previous reports that 
subunit-specific interaction between NR2B containing NMDARs and expanded mutant 
htt potentiate NMDAR-initiated apoptotic cell death and are important mediators of 
neurodegeneration in HD.  NMDAR antagonists are viable candidates as interventions in 
HD but it seems likely that highly selective NR2B antagonists will be the optimal 
candidate agents. 
METHODS 
Hdh150/+; NR2BTg/WT double mutant mice.  Interbreeding the Hdh(CAG)150 and NR2B 
transgenic lines results in four groups of mice, Hdh+/+; NR2BWT/WT (wild type 
huntingtin; no transgene), Hdh+/+; NR2BTg/WT (wild-type huntingtin; one copy of the 
NR2B transgene), Hdh150/+; NR2BWT/WT (one copy of mutant huntingtin; no transgene), 
Hdh150/+; NR2BTg/WT (one copy of mutant huntingtin; one copy of the NR2B transgene).  
All four groups were generated from the cross of the Hdh(CAG)150 mice murine 
model of HD maintained on a mixed genetic background 129/Ola and C57BL/J6 
expressing 75-90% C57BL/6; (Peter J. Detloff; unpublished data) with the NR2B 
transgenic mouse maintained on a genetic CBA/C57BL/6 F1 hybrid background  
resulting in the F1 mixed background 129/Ola and CBA/C57BL/J626.  Both male and 
female mice and their wild type littermates (WT) were used.  All animals were housed in 
cages grouped by gender and provided with food and water ad libitum.  Animals were 
housed in a Specific Pathogenic Free conditions with a 12-h light/dark cycle maintained 
at 23oC.  All procedures were conducted in strict compliance with the Guide for the Care 
and Use of Laboratory Animals as adopted by the NIH and approved by the Committee 
on Use and Care of Animals (UCUCA), University of Michigan, and the Veterinary 
Medical Unit (VMU) at the Ann Arbor Veterans Affairs Medical Center. 
Genotyping.  All mice studied were genotyped for both the Hdh allele and the NR2B 
transgene. The Hdh allele genotyping protocol is previously published26.  In brief, DNA 
was extracted from a 1 cm tail biopsy using a DNeasy Tissue Kit (Qiagen Inc.  Valencia, 
CA, USA).  Polymerase chain reaction (PCR) amplification was performed using a Taq 
polymerase kit and primers (purchased from Invitrogen, Carlsbad, CA) designed to flank 
the 150 CAG repeat in the Hdh locus  
Forward primer: CCCATTCATTGCCTTGCTGCTAGG,  
Reverse primer: CCTCTGGACAGGGAACAGTGTTGG.   
PCR conditions were as follows: 94°C for 5 min followed by 29 cycles at 94°C for 30 
sec, 63°C for 30 sec, 72°C for 3 min and a final extension at 72° for 5 min.  DNA 
products were separated by standard 1.5% agarose gel electrophoresis and were 
visualized with ethidium bromide using a Gel Doc system (Bio-Rad Laboratories, 
Hercules, CA).  Expected bands: 379 bp for wild type band, 829 bp for mutant band.  To 
confirm reliability of genotyping over time, periodic CAG sizing was performed outside 
our laboratory (Laragen Inc., Los Angeles, CA) to confirm consistency of the CAG 
repeat number, which ranged from 145-150 CAG repeats.  For the NR2B transgene, 
genotyping protocol is taken from46.  Briefly, genotypes were analyzed by extracting 
genomic DNA from tail biopsy. The 5' and 3' primers for detecting NR2B transgene 
SV40 polyA sequence (505 bp): 
5'-AGAGGATCTTTGTGAAGGAAC-3' and 5'-AAGTAAAACCTCTACAAATG-3', 
respectively.  Mouse tail DNAs (about 1μg) were amplified 30 cycles (1 min, 94oC; 45 
sec, 55 oC; 1 min, 72 oC) on a thermal cycler.  For zygosity testing, NR2B transgene 
detection was performed outside our laboratory (Charles River Laboratories Inc., 
Wilmington, MA). 
Euthanasia.  All animals were euthanized according to national guidelines.  Euthanasia 
was carried out by decapitation.  This method was approved by UCUCA and the VMU. 
Behavioral Examination.  Six behavioral assays used: 1) the accelerating rotarod, 2) the 
hanging wire test, 3) the tail suspension test, 4) activity monitoring, 5) footprint analysis, 
and 6) balance beam tests were used for each time point (20, 40, 50, 70, and 100 weeks26. 
Pathologic Analyses.  Immunohistochemistry, stereology, and receptor autoradiography 
analyses were performed as described previously26. Fresh frozen hemispheres were 
prepared for autoradiographic receptor binding analyses. Paraformaldehyde fixed 
hemispheres were prepared for stereological analysis.  Free floating sections were 
processed with either primary antisera against the neuronal antigen NeuN (Chemicon Int., 
Temecula, CA, USA; 1:100 dilution) or huntingtin (N-18) antibody (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA; 1:250 dilution).  
Unbiased stereological counts of striatal neurons were obtained from the striatum 
of animals at 70 and 100 weeks of age using the StereoInvestigator software (Micro-
Brightfield, Colchester, VT).  The optical fractionator method was used to generate an 
estimate of neuronal number with positively stained NeuN immunoreactive cells counted 
in an unbiased selection of serial sections in a defined volume of the striatum. Striatal 
volume was reconstructed by the StereoInvestigator software.  Serially cut sagittal tissue 
sections (every fourth section) were analyzed for one entire hemisphere of animals in 
each genotype cohort (n=4/group). 
Statistical Analyses.  All studies were performed blind to genotype.  Comparisons were 
performed on using one-way analysis of variance (ANOVA) with posthoc comparisons 
with the Tukey HSD when p < 0.05.  Repeated measures ANOVA was performed for 
behavioral tests requiring repeated tests.  A critical p < 0.05 was used for statistical 
significance in all analyses.  Huynh-Feldt adjustment was used in correcting for violation 
of sphericity when necessary to adjust non-uniform variance across days or groups.  
SPSS statistical software package was used. 
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Figure Legend 
 
Figure 1 Hdh150/+;NR2BTg/WT double mutant mice exhibit striatal neuron 
number and volume loss at 100 weeks. (a-d) Hdh150/+;NR2BTg/WT double mutant 
mice display atrophic and irregular shaped NeuN stained striatal neurons compared to 
control groups (Hdh+/+; NR2BWT/WT, Hdh+/+; NR2BTg/WT, and Hdh150/+ 
NR2BWT/WT). (e) Hdh150/+;NR2BTg/WT exhibit a 51% loss in striatal neuron number 
and a 36% reduction in striatal volume (f) compared to all three littermate control 
groups (Hdh+/+; NR2BWT/WT, Hdh+/+; NR2BTg/WT, and Hdh150/+ NR2BWT/WT). *p < 
0.05. Values are expressed as mean + SEM. N = 4 animals/group, scale bar = 20 μm. 
 
Figure 2 Hdh150/+;NR2BTg/WT double mutant mice exhibit reductions in 
striatal D1 and D2 receptor binding while Hdh150/+;NR2BWT/WT show an 
intermediate reduction at 100 weeks. Pseudocolor images of receptor binding. 
Autoradiographs were analyzed by quantitative densitometry using an MCID-M2 
image analysis system. Histograms show results of densitometric analysis of film 
images converted to pCi of 3H-ligand bound per gram of protein. Regions analyzed 
are the substantia nigra (SN), ventral striatum (ventral Str), dorsal striatum (dorsal 
Str), whole striatum (STR), cerebellum (Cer), hippocampus (HIP), thalamus (THAL), 
frontal cortex (FRCT), and whole brain (Whole).  (a) D1, D2, and GABAA receptor 
binding at 100 weeks (b-c) D1 and D2 receptor binding at 70 weeks. * p < 0.05. 
Values are expressed as mean pCi/g + SEM. 
 
Figure 3 Hdh150/+;NR2BTg/WT double mutant mice and 
Hdh150/+;NR2BWT/WT exhibit abundant striatal neuronal intranuclear inclusions 
(NIIs) at 70 weeks. (a-b) No NIIs in Hdh+/+; NR2BWT/WT, Hdh+/+; NR2BTg/WT mice. 
(c-d) Saturation of NIIs in the striatum of Hdh150/+;NR2BTg/WT and Hdh150/+ 
NR2BWT/WT mice. Arrows designate representative inclusions, scale bar = 50 μm. 
Inset are enlargements of arrows designating NIIs, scale bar = 100 μm. 
 
Figure 4 Hdh150/+;NR2BTg/WT bigenic mutant mice exhibit weight loss at 
100 weeks. Hdh150/+;NR2BTg/WT bigenic mutant mice exhibit significant weight loss 
compared to Hdh+/+; NR2BWT/WT, Hdh+/+; NR2BTg/WT, and Hdh150/+ NR2BWT/WT 
littermate controls. * p < 0.05. Values expressed as mean weight + SEM. 
 
Figure 5 Hdh150/+;NR2BTg/WT double mutant mice and 
Hdh150/+;NR2BWT/WT exhibit decreased locomotor activity and require more time to 
traverse the balance beam at 100 weeks. (a) Hdh150/+;NR2BTg/WT bigenic mutant 
mice show decreased photo beam breaks as measured in crossovers of activity cages 
at 100 weeks compared to Hdh+/+; NR2BWT/WT, Hdh+/+; NR2BTg/WT.  Hdh150/+ 
NR2BWT/WT also exhibit, to a lesser extent, decreased general activity compared to 
Hdh+/+; NR2BWT/WT.  (b) Mice were placed on a lit platform and traversed an 11 mm 
diameter round balance beam to reach a dark chamber. Animals are tested over eight 
days (1 trial/day). Both Hdh150/+;NR2BTg/WT double mutant mice and 
Hdh150/+;NR2BWT/WT require three times as long to traverse the balance beam 
compared to controls.  Hdh150/+;NR2BTg/WT and Hdh150/+ NR2BWT/WT require an 
average of 6.2 sec. + (SEM) 0.45 sec and Hdh+/+; NR2BWT/WT and Hdh+/+; 
NR2BTg/WT require 2.0 sec. + 0.44 sec. to traverse the beam. N = 8-9 animals/group. 
 
 
Supplemental  
 
Figure 1 Hdh150/+;NR2BTg/WT double mutant mice display abnormal gait at 
100 weeks. Gait was captured by painting the paws of animals with contrasting non-
toxic colors prior to walking a paper-lined corridor. Forepaws are painted in red and 
hindpaws are colored in blue. Hdh150/+;NR2BTg/WT mice reveal loss of gait pattern 
and shortening of stride length compared to all groups. Hdh+/+; NR2BWT/WT, 
Hdh+/+; NR2BTg/WT, and Hdh150/+ NR2BWT/WT display congruent overlap paw 
prints. 
 
Table 1 Ligand binding at 100 and 70 weeks. Radioactive ligands: 
[3H]SCH23390 (D1), [3H]Spiperone (D2), and [3H]Flunitrazepam (GABA). No 
significant differences between groups in all regions for [3H]Flunitrazepam/GABA 
binding. * p < 0.05 compared to wild type controls. All values are expressed as pCi/g 
± SEM. 
 





